Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report) was the recipient of a large increase in short interest in August. As of August 14th, there was short interest totaling 520 shares, an increase of ? from the July 30th total of 0 shares. Based on an average daily volume of 415 shares, the short-interest ratio is presently 1.3 days.
Silence Therapeutics Price Performance
OTCMKTS:SLNCF opened at $4.00 on Friday. The business’s 50-day moving average is $2.66 and its two-hundred day moving average is $2.11. Silence Therapeutics has a 12 month low of $1.06 and a 12 month high of $5.99.
Silence Therapeutics Company Profile
Silence Therapeutics is a clinical-stage biotechnology company focused on the development of small interfering RNA (siRNA) therapies designed to silence disease-causing genes. The company’s proprietary AtuRNAi platform employs ligand-conjugated siRNA to enable targeted delivery and extended duration of action, with the aim of addressing chronic and severe diseases. Silence Therapeutics advances its own pipeline programs while also forming strategic partnerships to leverage its delivery technology in indications such as cardiovascular disease, metabolic disorders and rare genetic conditions.
The company’s lead program, SLN360, is designed to reduce lipoprotein(a), a known independent risk factor for cardiovascular events, and is currently in clinical development.
Featured Stories
- Five stocks we like better than Silence Therapeutics
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
